Current Report Filing (8-k)
May 11 2017 - 4:08PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date
of Report: May 11, 2017
(Date of earliest event reported)
ImmuCell
Corporation
(Exact name of registrant as specified in its charter)
DE
(State or other jurisdiction
of incorporation)
|
001-12934
(Commission File Number)
|
01-0382980
(IRS Employer
Identification Number)
|
|
56
Evergreen Drive
Portland,
Maine
(Address of principal executive offices)
|
|
04103
(Zip Code)
|
207-878-2770
(Registrant's telephone number, including area code)
Not
Applicable
(Former Name or Former Address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant
under any of the following provisions:
|
☐
|
Written communications pursuant
to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule 14a-12
under the Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications pursuant to
Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement communications pursuant to
Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item
2.02. Results of Operations and Financial Condition
On
May 11, 2017 ImmuCell Corporation (the "Company") issued a press release announcing unaudited financial results for
the three-month period ended March 31, 2017. The full text of the press release issued in connection with the announcement is
attached as Exhibit 99.1 to this Current Report on Form 8-K.
The
information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange
Act") or otherwise subject to liabilities of that section, nor shall it be deemed incorporated by reference in any filing
under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits
.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
IMMUCELL CORPORATION
|
|
|
Date: May 11, 2017
|
By:
|
/s/
Michael F. Brigham
|
|
|
Michael F. Brigham
|
|
|
President,
Chief Executive Officer and Principal Financial Officer
|
Exhibit Index
ImmuCell (NASDAQ:ICCC)
Historical Stock Chart
From Mar 2024 to Apr 2024
ImmuCell (NASDAQ:ICCC)
Historical Stock Chart
From Apr 2023 to Apr 2024